MNTA - Momenta Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.38
+0.06 (+0.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close13.32
Open13.32
Bid13.46 x 1000
Ask13.47 x 800
Day's Range13.22 - 13.65
52 Week Range9.51 - 27.28
Volume397,754
Avg. Volume538,809
Market Cap1.321B
Beta (3Y Monthly)2.12
PE Ratio (TTM)N/A
EPS (TTM)-2.44
Earnings DateNov 4, 2019 - Nov 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors

    “We are excited to have Dr. Grogan join our Board.  She has led numerous investigational new drug applications and marketing authorization applications, and has extensive experience with international regulatory authorities,” said Craig Wheeler, President and Chief Executive Officer at Momenta Pharmaceuticals. “I am honored to join Momenta’s Board of Directors as the team makes strides in addressing the needs of patients with rare autoimmune diseases,” adds Dr. Donna Grogan.

  • Is Momenta Pharmaceuticals, Inc.'s (NASDAQ:MNTA) CEO Paid At A Competitive Rate?
    Simply Wall St.

    Is Momenta Pharmaceuticals, Inc.'s (NASDAQ:MNTA) CEO Paid At A Competitive Rate?

    Craig Wheeler became the CEO of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) in 2006. First, this article will compare...

  • Momenta (MNTA) Up 10% Since Last Earnings Report: Can It Continue?
    Zacks

    Momenta (MNTA) Up 10% Since Last Earnings Report: Can It Continue?

    Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Momenta Continues Its Transition
    Motley Fool

    Momenta Continues Its Transition

    Developing novel drugs takes time.

  • Thomson Reuters StreetEvents

    Edited Transcript of MNTA earnings conference call or presentation 2-Aug-19 12:30pm GMT

    Q2 2019 Momenta Pharmaceuticals Inc Earnings Call

  • Momenta Pharmaceuticals Inc (MNTA) Q2 2019 Earnings Call Transcript
    Motley Fool

    Momenta Pharmaceuticals Inc (MNTA) Q2 2019 Earnings Call Transcript

    MNTA earnings call for the period ending June 30, 2019.

  • Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss
    Zacks

    Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss

    Momenta (MNTA) reports a wider loss and misses on sales in Q2 .

  • Momenta Pharmaceuticals (MNTA) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    Momenta Pharmaceuticals (MNTA) Reports Q2 Loss, Misses Revenue Estimates

    Momenta (MNTA) delivered earnings and revenue surprises of -176.19% and -43.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results

    — Launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), the Company’s third study of its FcRn inhibitor; top-line data expected by.

  • GlobeNewswire

    Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation

    Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, announced the launch of an adaptive Phase 2/3 clinical study for its FcRn inhibitor nipocalimab (M281) in warm Autoimmune Hemolytic Anemia (wAIHA). This follows the acceptance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration. The FDA has also granted Fast Track Designation for nipocalimab in wAIHA.

  • GlobeNewswire

    Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)

    Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for M281, Momenta’s IgG1 monoclonal antibody targeting FcRn, in Hemolytic Disease of the Fetus and Newborn (HDFN). HDFN is a serious blood disorder in a fetus or newborn that occurs when red cell incompatibility exists between the blood types of a mother and baby.

  • Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast

    Management will host a conference call on August 2, 2019 at 8:30 a.m. ET to discuss these results and provide an update on the company. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. Momenta Pharmaceuticals is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases and advancing its late stage biosimilar portfolio.

  • GlobeNewswire

    Momenta Pharmaceuticals Announces Settlement Agreement with Amphastar Resolving Enoxaparin Sodium Injection Litigation

    Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Momenta, Sandoz AG and Amphastar Pharmaceuticals (the “parties”) have executed a mutually agreeable settlement agreement resolving all pending litigation between the parties related to enoxaparin sodium injection. “We are very pleased to have reached a comprehensive resolution with Amphastar resolving all of our outstanding litigation,” said Craig Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. Under terms of the settlement, the parties jointly requested the U.S. District Court for the District of Massachusetts (the “District Court”) to vacate the 2017 patent judgment relating to the parties.

  • Markit

    See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc.

    Momenta Pharmaceuticals Inc NASDAQ/NGS:MNTAView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for MNTA with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MNTA are favorable, with net inflows of $2.18 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Did You Manage To Avoid Momenta Pharmaceuticals's (NASDAQ:MNTA) 47% Share Price Drop?
    Simply Wall St.

    Did You Manage To Avoid Momenta Pharmaceuticals's (NASDAQ:MNTA) 47% Share Price Drop?

    The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...

  • GlobeNewswire

    Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference

    Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler, President and CEO, will present at the Goldman Sachs 40th Annual Global Healthcare Conference.  The presentation is scheduled for Tuesday, June 11, 2019 at 8:40 a.m. PT (11:40 a.m. ET). A webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event.

  • Momenta (MNTA) Down 16.6% Since Last Earnings Report: Can It Rebound?
    Zacks

    Momenta (MNTA) Down 16.6% Since Last Earnings Report: Can It Rebound?

    Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Thomson Reuters StreetEvents

    Edited Transcript of MNTA earnings conference call or presentation 2-May-19 12:30pm GMT

    Q1 2019 Momenta Pharmaceuticals Inc Earnings Call

  • GlobeNewswire

    Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference

    Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler, President and CEO, will present at the 2019 Bank of America Merrill Lynch Healthcare Conference.  The presentation is scheduled for Thursday, May 16, 2019 at 9:20 a.m. PT (12:20 p.m. ET). A webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com.  A replay of the presentation will be posted on the Momenta website approximately one hour after the event. Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases and advancing its late stage biosimilar portfolio.

  • Momenta Pharmaceuticals Wants to Be the "Humira of the FcRn Space"
    Motley Fool

    Momenta Pharmaceuticals Wants to Be the "Humira of the FcRn Space"

    It's going to take a few years to get there.

  • Hedge Funds Have Never Been This Bullish On Momenta Pharmaceuticals, Inc. (MNTA)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Momenta Pharmaceuticals, Inc. (MNTA)

    How do we determine whether Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]

  • Momenta Pharmaceuticals Inc (MNTA) Q1 2019 Earnings Call Transcript
    Motley Fool

    Momenta Pharmaceuticals Inc (MNTA) Q1 2019 Earnings Call Transcript

    MNTA earnings call for the period ending March 31, 2019.